WoodTrust Financial Corp trimmed its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 10.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,247 shares of the biopharmaceutical company’s stock after selling 847 shares during the period. WoodTrust Financial Corp’s holdings in Bristol-Myers Squibb were worth $367,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in the company. Marshall Wace North America L.P. increased its holdings in Bristol-Myers Squibb by 26.1% during the 1st quarter. Marshall Wace North America L.P. now owns 561,845 shares of the biopharmaceutical company’s stock worth $26,806,000 after purchasing an additional 116,315 shares in the last quarter. Princeton Global Asset Management LLC increased its holdings in Bristol-Myers Squibb by 9.3% during the 1st quarter. Princeton Global Asset Management LLC now owns 8,000 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 680 shares in the last quarter. Diversified Trust Co increased its holdings in Bristol-Myers Squibb by 32.8% during the 1st quarter. Diversified Trust Co now owns 16,255 shares of the biopharmaceutical company’s stock worth $776,000 after purchasing an additional 4,014 shares in the last quarter. Accident Compensation Corp bought a new stake in Bristol-Myers Squibb during the 1st quarter worth approximately $191,000. Finally, GYL Financial Synergies LLC bought a new stake in Bristol-Myers Squibb during the 1st quarter worth approximately $662,000. Hedge funds and other institutional investors own 80.25% of the company’s stock.
BMY has been the subject of a number of recent research reports. Bank of America boosted their price objective on Bristol-Myers Squibb from $49.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, October 10th. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Monday, October 7th. JPMorgan Chase & Co. set a $62.00 price objective on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday, September 13th. TheStreet raised Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. Finally, Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective for the company in a report on Wednesday, August 14th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $55.81.
In other news, Director Robert J. Bertolini acquired 11,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were acquired at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the completion of the purchase, the director now owns 11,397 shares in the company, valued at $509,673.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.13% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb stock traded up $0.27 during trading on Tuesday, hitting $51.83. The stock had a trading volume of 7,432,257 shares, compared to its average volume of 15,213,555. Bristol-Myers Squibb Co has a 1 year low of $42.48 and a 1 year high of $59.28. The company has a quick ratio of 3.75, a current ratio of 3.88 and a debt-to-equity ratio of 1.51. The stock’s 50 day moving average is $49.59 and its two-hundred day moving average is $47.11. The stock has a market cap of $84.34 billion, a price-to-earnings ratio of 13.02, a price-to-earnings-growth ratio of 2.54 and a beta of 0.72.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The business had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter in the prior year, the business earned $1.01 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 10.0% on a year-over-year basis. As a group, equities research analysts anticipate that Bristol-Myers Squibb Co will post 4.29 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be paid a $0.41 dividend. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a $1.64 annualized dividend and a yield of 3.16%. Bristol-Myers Squibb’s payout ratio is 41.21%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Further Reading: S&P 500 Index
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.